ChemoCentryx Inc. (NASDAQ:CCXI) insider Petrus Bekker sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $8.30, for a total transaction of $10,375.00. Following the transaction, the insider now directly owns 54,844 shares of the company’s stock, valued at approximately $455,205.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Petrus Bekker also recently made the following trade(s):

  • On Friday, November 11th, Petrus Bekker sold 33,332 shares of ChemoCentryx stock. The shares were sold at an average price of $8.00, for a total transaction of $266,656.00.

ChemoCentryx Inc. (NASDAQ:CCXI) opened at 7.87 on Friday. The stock’s market cap is $376.23 million. The firm has a 50-day moving average of $6.70 and a 200-day moving average of $5.22. ChemoCentryx Inc. has a 1-year low of $1.92 and a 1-year high of $8.37.

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Several institutional investors have recently modified their holdings of CCXI. Geduld E E acquired a new position in shares of ChemoCentryx during the second quarter valued at $112,000. KCG Holdings Inc. acquired a new position in shares of ChemoCentryx during the third quarter valued at $126,000. Alliancebernstein L.P. acquired a new position in shares of ChemoCentryx during the second quarter valued at $142,000. Bank of Montreal Can acquired a new position in shares of ChemoCentryx during the second quarter valued at $144,000. Finally, Emerald Acquisition Ltd. acquired a new position in shares of ChemoCentryx during the second quarter valued at $155,000. Hedge funds and other institutional investors own 48.09% of the company’s stock.

Several brokerages recently commented on CCXI. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research note on Monday. JPMorgan Chase & Co. reissued a “buy” rating and issued a $11.00 price target on shares of ChemoCentryx in a research note on Tuesday, August 9th.

ILLEGAL ACTIVITY NOTICE: “Petrus Bekker Sells 1,250 Shares of ChemoCentryx Inc. (CCXI) Stock” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/25/petrus-bekker-sells-1250-shares-of-chemocentryx-inc-ccxi-stock.html.

ChemoCentryx Company Profile

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

5 Day Chart for NASDAQ:CCXI

Receive News & Stock Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related stocks with our FREE daily email newsletter.